Compositions and methods for rapid immunization against dengue virus
AssigneeTakeda Vaccines, Inc.
InventorsDan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
Claims37
1-24. (canceled)
A method for inducing an immune response in a subject against three or more dengue virus serotypes, the method comprising:
- administering a first immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone;
- and
- administering a second immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone;
- wherein the first immunogenic composition and the second immunogenic composition are administered at the same anatomical location on the same day to the subject;
- and
- inducing an immune response in the subject against the three or more dengue virus serotypes.
(canceled)
30-31. (canceled)
A method for inducing an immune response in a subject against three or more dengue virus serotypes, the method comprising:
- administering a first immunogenic composition of a monovalent live, attenuated dengue virus;
- administering a second immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone;
- and;
- wherein the first immunogenic composition and the second immunogenic composition are administered at two or more anatomical locations consecutively on the same day to the subject;
- and
- inducing an immune response in the subject against the three or more dengue virus serotypes.
42-43. (canceled)
(canceled)
Dependencies are inferred from the claim text.